| Patent application number | Description | Published |
|---|
| 20090081199 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 03-26-2009 |
| 20090214557 | BIOLOGICALLY ACTIVE ANTIBODIES RECOGNIZING A CELL SURFACE MOLECULE SELECTIVELY EXPRESSED ON LIVING MOUSE NATURAL TYPE ONE (I) INTERFERON PRODUCING CELLS - An isolated and characterized monoclonal antibody (“440 | 08-27-2009 |
| 20100305306 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 12-02-2010 |
| 20100306863 | SCREENING, THERAPY AND DIAGNOSIS - A TREM-1 ligand is identified. This allows various derivatives to be provided/identified that are capable of binding to the TREM-1 receptor. The TREM-1 ligand or the derivatives can be used in screening for drugs/drug candidates. Substances that block or reduce binding of the TREM-1 ligand/derivative to a TREM-1 receptor may be useful for treating sepsis, particularly sepsis of bacterial or fungal origin. Antibodies to the ligand may be useful in diagnosing sepsis, particularly sepsis of bacterial or fungal origin. | 12-02-2010 |
| 20100310560 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR | 12-09-2010 |
| Patent application number | Description | Published |
|---|
| 20080277545 | Medical device clamp - A medical instrument device interconnection system decreases the vibrational effects on a hospital pole. The medical device is contained in a case and the case has a first clamping member, a first biasing apparatus, a second clamping member, a second biasing apparatus, and a pole receiving trench. Each clamping member has a preferred position, an attachment position and a maximum tension position. In the preferred position the respective biasing members position the respective clamping member's distal end as close to each other as possible which inhibits a conventional hospital pole from entering the pole receiving trench. To obtain the maximum tension position, the person positioning the medical instrument device on the hospital pole aligns the pole receiving trench with the hospital pole so the hospital pole contacts the clamping members' exterior surface in the preferred position. The person raises the device in relation to the pole which causes the clamping members to rotate and expose the pole receiving trench. Once the hospital pole enters the pole receiving trench the respective biasing apparatus on each clamping member has the respective clamping members revert toward the preferred position. The preferred position cannot be obtained because the hospital pole in the pole receiving trench inhibits the clamping members from reverting to that position. Instead the clamping members are in the attachment position after the medical instrument device is lowered a little in relation to the hospital pole to obtain the maximum force in the attachment position. Collectively the biasing apparatuses through the clamping members in the attachment position provide more force to the hospital pole than the weight of the medical instrument device. That way the medical instrument device remains attached to the hospital pole and due to the flexible biasing apparatuses the device's vibration is suppressed while attached to the hospital pole. | 11-13-2008 |
| 20080281387 | Medical Device Clamp - A medical instrument device interconnection system decreases the vibrational effects on a hospital pole. The medical device is contained in a case and the case has a first clamping member, a first biasing apparatus, a second clamping member, a second biasing apparatus, and a pole receiving trench. Each clamping member has a preferred position, an attachment position and a maximum tension position. In the preferred position the respective biasing members position the respective clamping member's distal end as close to each other as possible which inhibits a conventional hospital pole from entering the pole receiving trench. To obtain the maximum tension position, the person positioning the medical instrument device on the hospital pole aligns the pole receiving trench with the hospital pole so the hospital pole contacts the clamping members' exterior surface in the preferred position. The person raises the device in relation to the pole which causes the clamping members to rotate and expose the pole receiving trench. Once the hospital pole enters the pole receiving trench the respective biasing apparatus on each clamping member has the respective clamping members revert toward the preferred position. The preferred position cannot be obtained because the hospital pole in the pole receiving trench inhibits the clamping members from reverting to that position. Instead the clamping members are in the attachment position after the medical instrument device is lowered a little in relation to the hospital pole to obtain the maximum force in the attachment position. Collectively the biasing apparatuses through the clamping members in the attachment position provide more force to the hospital pole than the weight of the medical instrument device. That way the medical instrument device remains attached to the hospital pole and due to the flexible biasing apparatuses the device's vibration is suppressed while attached to the hospital pole. | 11-13-2008 |
